Gan & Lee Pharmaceuticals.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Ganli Pharmaceutical Co., Ltd. was established in 1998 and is a high-tech biopharmaceutical enterprise that integrates research, development, production, and sales. Headquartered in the southern district of Tongzhou Economic Development Zone in Beijing, it is part of the Zhongguancun National Independent Innovation Demonstration Zone and has an industrial park of approximately 200000 square meters. As the first company in China to master the technology of industrialized production of recombinant insulin analogues, Ganli Pharmaceutical is in a leading position in the Chinese diabetes market in terms of research, development and production of biosynthetic human insulin and its analogues. It has established close cooperation with well-known enterprises such as Sandoz, a subsidiary of Novartis, and actively explored overseas markets. As a global enterprise focusing on human health, Ganli Pharmaceutical adheres to the scientific and ultimate corporate culture, and is committed to providing high-quality products and services for diabetes patients worldwide. |
| Headquarter | Beijing |
| Establish Date | 6/17/1998 |
| Listed Code | 603087.SH |
| Listed Date | 6/29/2020 |
| Chairman | Gan Zhongru. |
| CEO | Dukai. |
| Website | www.ganlee.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
